Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 8 | Longs Won 3/8 37% | Profit Factor 0.08 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $12,612.25 |
| Average Win $1,642.76 | Best Trade (Jul 07) $2,277.54 | Sharpe Ratio -30.98 |
| Average Loss -$11,667.49 | Worst Trade (Oct 12) -$36,207.28 | Z-Score -0.21 (16.32%) |
| Commissions $0 | Avg. Trade Length 1m 6d | Expectancy -$6,676.15 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 4 | 4 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 0 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
COAG Hemab Therapeutics Holdings, Inc. | 1,458.7 | $44,329.83 | $46,590.81 | - | $2,260.98 | 5.1% | +6.68% |